Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications

Metastatic dissemination of tumor cells is responsible for the fatal outcome of breast cancer. Therefore, understanding the mechanisms involved in dissemination is essential for the development of new therapeutic strategies to prevent metastasis. One mechanism involved in metastatic dissemination of...

Full description

Bibliographic Details
Main Authors: Ana Orive‐Ramos, Samuel Seoane, Alberto Ocaña, Atanasio Pandiella, Juan Carlos Montero
Format: Article
Language:English
Published: Wiley 2017-12-01
Series:Molecular Oncology
Subjects:
SRC
Online Access:https://doi.org/10.1002/1878-0261.12145
id doaj-24a2768018694eb8985ee922cb493477
record_format Article
spelling doaj-24a2768018694eb8985ee922cb4934772020-11-25T03:50:46ZengWileyMolecular Oncology1574-78911878-02612017-12-0111121788180510.1002/1878-0261.12145Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implicationsAna Orive‐Ramos0Samuel Seoane1Alberto Ocaña2Atanasio Pandiella3Juan Carlos Montero4Instituto de Biología Molecular y Celular del Cáncer (IBMCC‐CIC) CSIC Salamanca SpainInstituto de Biología Molecular y Celular del Cáncer (IBMCC‐CIC) CSIC Salamanca SpainUnidad de Investigación Traslacional Hospital Universitario de Albacete Universidad de Castilla La Mancha Albacete SpainInstituto de Biología Molecular y Celular del Cáncer (IBMCC‐CIC) CSIC Salamanca SpainInstituto de Biología Molecular y Celular del Cáncer (IBMCC‐CIC) CSIC Salamanca SpainMetastatic dissemination of tumor cells is responsible for the fatal outcome of breast cancer. Therefore, understanding the mechanisms involved in dissemination is essential for the development of new therapeutic strategies to prevent metastasis. One mechanism involved in metastatic dissemination of breast cancer cells is dependent on control of the production of matrix metalloproteinases by the neuregulins (NRGs). The NRGs are polypeptide factors that act by binding to the ErbB/HER subfamily of receptor tyrosine kinases. NRG‐mediated activation of HER receptors causes an increase in the production of metalloprotease 13 (MMP13, also termed collagenase‐3), which facilitates metastatic dissemination of breast tumors. In this context, we aimed to explore whether the clinically approved tyrosine kinase inhibitor dasatinib was able to neutralize this mechanism of metastatic dissemination. Here, we show that dasatinib restricted NRG‐induced MMP13 upregulation, both in vitro and in vivo, and in vivo metastatic dissemination of breast cancer cells. Chemical proteomics studies showed that the main cellular targets of dasatinib were SRC family kinases (SFKs). Moreover, genetic studies showed that knockdown of SRC or YES strongly inhibited NRG‐induced MMP13 upregulation in vitro. Mechanistically, dasatinib treatment or knockdown of SRC also inhibited ERK1/2 kinases in vitro, which were required for NRG‐induced MMP13 upregulation. These results open the possibility of clinically exploring the antitumoral action of dasatinib in those tumors in which the NRG–MMP13 signaling axis may play a relevant role in the control of tumor cell dissemination.https://doi.org/10.1002/1878-0261.12145breast cancer disseminationdasatinibMMP13neuregulinSRC
collection DOAJ
language English
format Article
sources DOAJ
author Ana Orive‐Ramos
Samuel Seoane
Alberto Ocaña
Atanasio Pandiella
Juan Carlos Montero
spellingShingle Ana Orive‐Ramos
Samuel Seoane
Alberto Ocaña
Atanasio Pandiella
Juan Carlos Montero
Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
Molecular Oncology
breast cancer dissemination
dasatinib
MMP13
neuregulin
SRC
author_facet Ana Orive‐Ramos
Samuel Seoane
Alberto Ocaña
Atanasio Pandiella
Juan Carlos Montero
author_sort Ana Orive‐Ramos
title Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
title_short Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
title_full Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
title_fullStr Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
title_full_unstemmed Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
title_sort regulation of the prometastatic neuregulin–mmp13 axis by src family kinases: therapeutic implications
publisher Wiley
series Molecular Oncology
issn 1574-7891
1878-0261
publishDate 2017-12-01
description Metastatic dissemination of tumor cells is responsible for the fatal outcome of breast cancer. Therefore, understanding the mechanisms involved in dissemination is essential for the development of new therapeutic strategies to prevent metastasis. One mechanism involved in metastatic dissemination of breast cancer cells is dependent on control of the production of matrix metalloproteinases by the neuregulins (NRGs). The NRGs are polypeptide factors that act by binding to the ErbB/HER subfamily of receptor tyrosine kinases. NRG‐mediated activation of HER receptors causes an increase in the production of metalloprotease 13 (MMP13, also termed collagenase‐3), which facilitates metastatic dissemination of breast tumors. In this context, we aimed to explore whether the clinically approved tyrosine kinase inhibitor dasatinib was able to neutralize this mechanism of metastatic dissemination. Here, we show that dasatinib restricted NRG‐induced MMP13 upregulation, both in vitro and in vivo, and in vivo metastatic dissemination of breast cancer cells. Chemical proteomics studies showed that the main cellular targets of dasatinib were SRC family kinases (SFKs). Moreover, genetic studies showed that knockdown of SRC or YES strongly inhibited NRG‐induced MMP13 upregulation in vitro. Mechanistically, dasatinib treatment or knockdown of SRC also inhibited ERK1/2 kinases in vitro, which were required for NRG‐induced MMP13 upregulation. These results open the possibility of clinically exploring the antitumoral action of dasatinib in those tumors in which the NRG–MMP13 signaling axis may play a relevant role in the control of tumor cell dissemination.
topic breast cancer dissemination
dasatinib
MMP13
neuregulin
SRC
url https://doi.org/10.1002/1878-0261.12145
work_keys_str_mv AT anaoriveramos regulationoftheprometastaticneuregulinmmp13axisbysrcfamilykinasestherapeuticimplications
AT samuelseoane regulationoftheprometastaticneuregulinmmp13axisbysrcfamilykinasestherapeuticimplications
AT albertoocana regulationoftheprometastaticneuregulinmmp13axisbysrcfamilykinasestherapeuticimplications
AT atanasiopandiella regulationoftheprometastaticneuregulinmmp13axisbysrcfamilykinasestherapeuticimplications
AT juancarlosmontero regulationoftheprometastaticneuregulinmmp13axisbysrcfamilykinasestherapeuticimplications
_version_ 1724490665110274048